ABCC8 and brain injury: Glibenclamide (5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide, C23H28ClN3O5S) [10,11] (Figure 1), a sulfonylurea receptor 1-transient receptor potential melastatin 4 (SUR1-TRPM4) channel blocker, has shown neuroprotective effects by reducing edema and maintaining the integrity of the endothelium and the blood–brain barrier [12,13] in preclinical models of brain injury [14,15].